Acromegaly is a rare, but serious hormonal disorder affecting approximately 60 people per million; recent studies suggest that the prevalence may be between 115-295 people per million worldwide.
Learn about advanced breast cancer and the targeted therapies that Novartis Oncology is exploring for estrogen receptor-positive breast cancer cells and the PI3K/AKT/mTOR pathway.
Learn about ALK+ advanced non-small cell lung cancer (NSCLC) and Novartis Oncology’s commitment to research & development for patients living with this genetically driven disease.
Learn about bone metastasis and Novartis Oncology's commitment to research & development for patients living with bone metastases.
Learn about chronic iron overload and what Novartis Oncology is doing to help lower liver iron concentration and serum ferritin of patients living with transfusion-dependent anemias.
Chronic myeloid leukemia, or CML, is a relatively slow-growing cancer of the blood and bone marrow, which affects one to two people in every 100,000 people every year.
Cushing's disease is a rare pituitary disorder associated with a 50% survival rate at 5 years if left untreated.
Learn about gastrointestinal stromal tumors (GIST) and Novartis Oncology's commitment to discovering therapies for patients living with GIST.
Learn about immune thrombocytopenia (ITP) and what Novartis Oncology is doing to help patients living with this rare and potentially serious blood disorder.
Learn about metastatic melanoma and Novartis Oncology’s commitment to research & development for patients living with this type of skin cancer.
Learn about multiple myeloma and Novartis Oncology’s commitment to research & development for patients living with this rare cancer.
Myelofibrosis is a rare and life-threatening blood cancer that affects approximately 1 in every 100,000 people.
Neuroendocrine tumors (NET) are a rare type of cancer that originate in neuroendocrine cells throughout the body.
Polycythemia vera is a rare and incurable blood cancer associated with an overproduction of blood cells in the bone marrow that affects up to three people per 100,000 globally.
Approximately 80% of patients with tuberous sclerosis complex (TSC) are living with renal angiomyolipomas.
Learn about renal cell carcinoma and Novartis Oncology's commitment to discovering therapies for patients living with kidney cancer.
Approximately 20% of patients with tuberous sclerosis complex (TSC) are living with subependymal giant cell astrocytoma (SEGA).
Soft tissue sarcoma (STS) is a malignant tumor of connective tissue, accounting for about 1% of all human cancers.
This site is intended for a global audience.